When it comes to psoriatic arthritis clinical trials such as TICOPA (tight control in PsA) have consistently shown that treating to target correlates with improved disease domain and patient reported outcomes. Minimal disease activity (MDA) has become an oft used target and outcome in PsA trials. While many of us measure and record a variety of measures in our patient charts, we may be on our way to demonstrating MDA in practice.
A single ultrasound guided intra-articular hip corticosteroid injection can be quite effective in patients with hip osteoarthritis (OA).
Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.
PsA Panelists included:
- Tena Brown
- Christine Lindsay
- Ashley Krivohlavek
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!
A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis.
Without question, basic immunology is at the foundation of rheumatology as a discipline. Indeed, for many rheumatologists, it was the intricacies of the immune system that attracted us into the field. With each passing year, extraordinary advances in scientific methods begat tremendous gains in our understanding of the immune system. Excitingly, we may be entering a new era, driven by results in psoriatic arthritis and other related
An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.
With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.
Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
Hopes that biologic drugs for rheumatoid arthritis (RA) would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.
Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.
In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said.
Among 158 patients randomized to tacrolimus, 83.0% achieved complete or partial responses after 24 weeks versus 75.0% of 156 assigned to intravenous cyclophosphamide, according to Zhaohui Zheng, MD, of Zhengzhou University in China, and colleagues.
Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series.
Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.
